ArticleTurkish journal of pharmaceutical sciences2025
Article in Turkish journal of pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hino-Fe Chelate Suppresses Osteosarcoma Progression through Dual Induction of Ferroptosis and NLRC4-mediated Pyroptosis: Mechanisms and Therapeutic Implications.International journal of biological sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The present study aimed to assess the antiproliferative and pro-apoptotic effects of hinokitiol in osteosarcoma cells Materials and Methods: The (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to evaluate the cytotoxic potential of hinokitiol in osteosarcoma cells. Various concentrations of hinokitiol (5, 10, 20, 40, 60, and 80 μg/mL) were tested, and the half-maximal inhibitory concentration (IC Results: Hinokitiol significantly ( Conclusion: According to the current study findings, hinokitiol prevented Morphological study of the effects of hinokitiol on osteosarcoma cells from proliferating, migrating, and induced apoptosis by upregulating BAX (a pro-apoptotic signal) expression and downregulating BCL-2 (anti-apoptotic signal) expression in osteosarcoma cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.